Network metaanalysis and cost per responder of tumor necrosis factor, interleukin, and phosphodiesterase inhibitors in the treatment of psoriatic arthritis

被引：0
|
作者：
Strand, Vibeke [1 ]
Husni, M. Elaine [2 ]
Griffith, Jenny [3 ]
Betts, Keith [4 ]
Beppu, Marci [3 ]
Song, Yan [4 ]
Ganguli, Arijit [3 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Anal Grp Inc, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
2534
引用
收藏
页码：AB260 / AB260
页数：1
相关论文
共 50 条
  • [31] Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab
    Edmund Cauza
    Marita Spak
    Karla Cauza
    Ursula Hanusch-Enserer
    Attila Dunky
    Ernst Wagner
    Rheumatology International, 2002, 22 : 227 - 232
  • [32] Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
    Gisondi, Paolo
    Geat, Davide
    Maurelli, Martina
    Degli Esposti, Luca
    Bellinato, Francesco
    Girolomoni, Giampiero
    VACCINES, 2022, 10 (05)
  • [33] TUMOUR NECROSIS FACTOR INHIBITORS PERSISTENCE IN PSORIATIC ARTHRITIS PATIENTS
    Vieira-Sousa, E.
    Eusebio, M.
    Avila-Ribeiro, P.
    Khmelinskii, N.
    Machado, A. R.
    Martins Rocha, T.
    Bernardes, M.
    Santos-Faria, D.
    Leite Silva, J.
    Santos, H.
    Miguel, C.
    Carvalho, P.
    Costa, T.
    Teixeira, L.
    Meirinhos, T.
    Nero, P.
    Santos, M. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1584 - 1585
  • [34] Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors
    Lubrano, Ennio
    Parsons, Wendy J.
    Perrotta, Fabio Massimo
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (05) : 918 - 923
  • [35] Risk of serious infections among new users of Interleukin-17, Interleukin-12/23 inhibitors, compared to tumor necrosis factor (TNF)-alpha inhibitors, for the treatment of psoriasis and psoriatic arthritis
    Li, Xintong
    Andersen, Kathleen M.
    Chang, Hsien-Yen
    Curtis, Jeffrey R.
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 420 - 421
  • [36] Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis
    Choquette, Denis
    Sauvageau, Loic Choquette
    Bessette, Louis
    Ferdinand, Isabelle
    Haraoui, Boulos
    Massicotte, Frederic
    Pelletier, Jean-Pierre
    Raynauld, Jean-Pierre
    Remillard, Marie-Anais
    Sauvageau, Diane
    Villeneuve, Edith
    Coupal, Louis
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [37] Inhibitors of tumor necrosis factor: New treatment options for rheumatoid arthritis
    Moreland, LW
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 1999, 66 (06) : 367 - 374
  • [38] Comparing Drug Survival between Five Tumor Necrosis Factor Inhibitors in Patients with Psoriatic Arthritis
    Kaloty, Roopinder
    Got, Tiffany
    Soucy, Elaine
    Chow, Andrew
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1514 - 1514
  • [39] Tumor necrosis factor inhibitors for rheumatoid arthritis
    Dentener, Mieke A.
    Wouters, Emiel F. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (19): : 2047 - 2048
  • [40] Inhibitors of tumor necrosis factor for rheumatoid arthritis
    Moreland, LW
    JOURNAL OF RHEUMATOLOGY, 1999, 26 : 7 - 15
12345